Donor Species Richness Determines Faecal Microbiota Transplantation Success in XXXX .

@entity1 @entity31 @entity29 @entity2718 @entity30 @entity1851
BACKGROUND AND AIMS: Faecal microbiota transplantation is a successful therapy for @entity1 with refractory @entity2718 infections. It has also been suggested as a treatment option for @entity29 , given the role of the intestinal microbiota in this disease. We assessed the impact of faecal microbiota transplantation in @entity1 with @entity29 and studied predictors of clinical (non-)response in microbial profiles of donors and @entity1 . METHODS: Fourteen refractory @entity1 (8 with @entity31 and 6 with @entity30 ) underwent ileocolonoscopy with faecal microbiota transplantation through a nasojejunal (n = 9) or rectal (n = 5) tube. Efficacy was assessed by endoscopic healing at week 8, clinical activity scores and @entity1851 measurement. Faecal microbiota was analysed by 16S rDNA pyrosequencing. RESULTS: There was no significant improvement among the 6 @entity1 with @entity30 at week 8 following faecal microbiota transplantation. One @entity1 experienced temporary clinical remission for 6 weeks. In contrast, 2/8 @entity1 with @entity31 had endoscopic remission at week 8, and of the 6 remaining @entity1 with @entity31 , 1 reported temporary remission for 6 weeks. The donor microbiota richness and the number of transferred phylotypes were associated with treatment success. Persistent increased @entity1851 2 weeks after transplantation was predictive of failure of response. CONCLUSION: Faecal microbiota transplantation led to endoscopic and long-term (>2 years) remission in 2 out of 8 @entity31 @entity1 . Higher donor richness was associated with successful transplant. Therefore, faecal microbiota transplantation with donor prescreening could be a treatment option for selected refractory @entity31 @entity1 .
